Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ARDS according to Berlin's definition~* PCR confirmed COVID-19~* Length of mechanical ventilation less or equal to 72 hours~Exclusion Criteria:~* Pregnancy or breast-feeding women~* Terminal illness with very poor prognosis according to the investigator judgement~* Therapeutic limitation~* Known immunocompromised condition~* Chronic use of systemic corticosteroids~* Participation in another randomized crinical trial~* More than 5 days of treatment of low dose dexamethasone for COVID-19~* Abscence of informed consent~* Active participation in other randomized clinical trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High dose Dexamethasone (Type: EXPERIMENTAL): Intravenous Dexamethasone 16 mg qd from day 1 to 5 followed by 8 mg qd from day 6 to 10
- Usual care - low dose Dexamethasone (Type: NO_INTERVENTION): Intravenous Dexamethasone 6 mg qd for 10 days based on RECOVERY trial

Based on this trial design, predict the completion outcome and termination type (if applicable).